Literature DB >> 26242463

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

F Perner1, T M Schnöder1, S Ranjan2, D Wolleschak1, C Ebert1, M C Pils3, S Frey1, A Polanetzki1, C Fahldieck1, U Schönborn1, B Schraven4,5, B Isermann2, T Fischer1, F H Heidel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26242463     DOI： 10.1038/leu.2015.218

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Authors:  Srdan Verstovsek; Constantine S Tam; Martha Wadleigh; Lubomir Sokol; Catherine C Smith; Lynne A Bui; Chunyan Song; Douglas O Clary; Patrycja Olszynski; Jorge Cortes; Hagop Kantarjian; Neil P Shah
Journal:  Leuk Res       Date:  2013-12-11       Impact factor: 3.156

2.  Bilateral toxoplasmosis retinitis associated with ruxolitinib.

Authors:  Roger A Goldberg; Elias Reichel; Lauren J Oshry
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

3.  Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

Authors:  G Caocci; F Murgia; L Podda; A Solinas; S Atzeni; G La Nasa
Journal:  Leukemia       Date:  2013-08-09       Impact factor: 11.528

4.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

5.  JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Authors:  Sowmya Parampalli Yajnanarayana; Thomas Stübig; Isabelle Cornez; Haefaa Alchalby; Kathrin Schönberg; Janna Rudolph; Ioanna Triviai; Christine Wolschke; Annkristin Heine; Peter Brossart; Nicolaus Kröger; Dominik Wolf
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

6.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

7.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

Review 8.  Cytokine signaling modules in inflammatory responses.

Authors:  John J O'Shea; Peter J Murray
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

9.  An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Authors:  Nicholas G Wysham; Donald R Sullivan; Gopal Allada
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.

Authors:  Claudia Colomba; Raffaella Rubino; Lucia Siracusa; Francesco Lalicata; Marcello Trizzino; Lucina Titone; Manlio Tolomeo
Journal:  BMC Res Notes       Date:  2012-10-05
View more
  12 in total

1.  Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.

Authors:  Caroline Ebert; Florian Perner; Denise Wolleschak; Tina M Schnöder; Thomas Fischer; Florian H Heidel
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

Review 2.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 3.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

4.  Gain of function in Jak2V617F-positive T-cells.

Authors:  G Nishanth; D Wolleschak; C Fahldieck; T Fischer; A Mullally; F Perner; T M Schnöder; S Just; F H Heidel; D Schlüter
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

Review 5.  JAK inhibition as a new treatment strategy for patients with COVID-19.

Authors:  Jin Huang; Chi Zhou; Jinniu Deng; Jianfeng Zhou
Journal:  Biochem Pharmacol       Date:  2022-07-03       Impact factor: 6.100

6.  Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.

Authors:  Zhenpeng Dai; James Chen; Yuqian Chang; Angela M Christiano
Journal:  JCI Insight       Date:  2021-04-08

7.  Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.

Authors:  F Heidel; A Hochhaus
Journal:  Leukemia       Date:  2020-06-11       Impact factor: 11.528

Review 8.  Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.

Authors:  Florian Perner; Caroline Perner; Thomas Ernst; Florian H Heidel
Journal:  Cells       Date:  2019-08-08       Impact factor: 6.600

9.  The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.

Authors:  Han Wang; Xinxia Feng; Ping Han; Yu Lei; Yujia Xia; Dean Tian; Wei Yan
Journal:  Mol Med Rep       Date:  2019-10-16       Impact factor: 2.952

10.  Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.

Authors:  A D'Alessio; P Del Poggio; F Bracchi; G Cesana; N Sertori; D Di Mauro; A Fargnoli; M Motta; C Giussani; P Moro; G Vitale; M Giacomini; G Borra
Journal:  Leukemia       Date:  2020-11-10       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.